Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Designer monotransregulators provide a basis for a transcriptional therapy for de novo endocrine-resistant breast cancer.

Designer monotransregulators provide a basis for a transcriptional therapy for de novo endocrine-resistant breast cancer. Mol Med. 2010 Jan-Feb; 16(1-2):10-8.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.